Back to Search
Start Over
Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools
- Source :
- Biomedicine & Pharmacotherapy, Biomedicine & Pharmacotherapy, Vol 128, Iss, Pp 110316-(2020)
- Publication Year :
- 2020
- Publisher :
- The Author(s). Published by Elsevier Masson SAS., 2020.
-
Abstract
- Graphical abstract<br />Highlights • Pudilan (PDL) was proven to be useful in the treatment of 2019 novel coronavirus disease (COVID-19). • Pudilan (PDL) might inhibit the cytokine storm in 2019 novel coronavirus disease (COVID-19) by affecting Interleukin-1β (IL-1β) and related proteins. • Pudilan (PDL) might prevent the entry of SARS-CoV-2 into cells by affecting angiotensin I converting enzyme 2 (ACE2). • Pudilan (PDL) might also moderate human immune system with traditional Chinese medicine theory.<br />Background Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. Methods We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. Results PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate. Conclusion PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.
- Subjects :
- 0301 basic medicine
Chemokine
SFJD, shufeng jiedu fang (TCM herbs)
Anti-Inflammatory Agents
Angiotensin-Converting Enzyme Inhibitors
Targeted therapy
0302 clinical medicine
Interferon
Transforming Growth Factor beta
Epidermal growth factor receptor
Protein Interaction Maps
BXTM, banxia tianma baizhu tang (TCM herbs)
biology
Interleukin
General Medicine
HSZF, hanshi zufei fang (TCM herbs)
Molecular Docking Simulation
030220 oncology & carcinogenesis
Tumor necrosis factor alpha
Angiotensin-Converting Enzyme 2
TCM, traditional Chinese medicine
Coronavirus Infections
Cytokine Release Syndrome
medicine.drug
Pneumonia, Viral
RM1-950
Peptidyl-Dipeptidase A
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Antiviral Agents
CCL5
Article
PDL, Pudilan (TCM herbs)
03 medical and health sciences
Betacoronavirus
Interferon-gamma
Immune system
stomatognathic system
medicine
Humans
Immunologic Factors
LHQW, lian hua qing wen (TCM herbs)
Pandemics
ARDS, acute respiratory distress syndrome
ComputingMethodologies_COMPUTERGRAPHICS
Pharmacology
business.industry
SARS-CoV-2
SARS-CoV-2 infection
Interleukins
COVID-19, 2019 novel coronavirus disease
COVID-19
Virus Internalization
medicine.disease
030104 developmental biology
Cancer research
biology.protein
ACE2, angiotensin I converting enzyme 2
Traditional Chinese herbs
Therapeutics. Pharmacology
Cytokine storm
business
Network pharmacology
Drugs, Chinese Herbal
Subjects
Details
- Language :
- English
- ISSN :
- 19506007 and 07533322
- Volume :
- 128
- Database :
- OpenAIRE
- Journal :
- Biomedicine & Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....37c4becf60373d971e8a583967aefccf